Shields RK, Paterson DL, Tamma PD. navigating available treatment options for carbapenem-resistant Acinetobacter baumannii–calcoaceticus complex infections. Clin Infect Dis. 2023;76(Suppl 2):S179–93.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–40.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of america guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–114.
Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–47.
Seifert H, Blondeau J, Lucaßen K, Utt EA. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016–2018). J Glob Antimicrob Resist. 2022;31:82–9.
Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii–calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother. 2022;66(9): e0078122.
Iovleva A, Mustapha MM, Griffith MP, Komarow L, Luterbach C, Evans DR, et al. Carbapenem-resistant Acinetobacter baumannii in US hospitals: diversification of circulating lineages and antimicrobial resistance. MBio. 2022;13(2):0275921.
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-Negative Bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968-e2017.
Flamm RK, Shortridge D, Castanheira M, Sader HS, Pfaller MA. In vitro activity of minocycline against U.S. isolates of acinetobacter baumannii-acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: results from the SENTRY Antimicrobial surveillance program, 2014 to 2018. Antimicrob Agents Chemother. 2019;63(11):e01154-19.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the american college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.
Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O’Hara JA, Doi Y, et al. In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother. 2014;58(2):1195–9.
Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26(9):1185–91.
Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. http://www.eucast.org. Accessed 17 April 2024.
Lertsrisatit Y, Santimaleeworagun W, Thunyaharn S, Traipattanakul J. In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A baumannii at a Thai university hospital. Infect Drug Resist. 2017;10:437–43.
Pankey G, Ashcraft D, Kahn H, Ismail A. Time-kill assay and Etest evaluation for synergy with polymyxin B and fluconazole against Candida glabrata. Antimicrob Agents Chemother. 2014;58(10):5795–800.
Ku NS, Lee SH, Lim YS, Choi H, Ahn JY, Jeong SJ, et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep. 2019;9(1):17127.
Boncompagni SR, Micieli M, Di Maggio T, Aiezza N, Antonelli A, Giani T, et al. Activity of fosfomycin/colistin combinations against planktonic and biofilm gram-negative pathogens. J Antimicrob Chemother. 2022;77(8):2199–208.
Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10):647.
Abdul-Mutakabbir JC, Yim J, Nguyen L, Maassen PT, Stamper K, Shiekh Z, et al. In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii. Antibiotics (Basel). 2021;10(7):880.
Jiang Z, He X, Li J. Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis. Infect Drug Resist. 2018;11:1083–95.
Yavaş S, Yetkin MA, Kayaaslan B, Baştuğ A, Aslaner H, But A, et al. Investigating the in vitro synergistic activities of several antibiotic combinationsagainst carbapenem-resistant Acinetobacter baumannii isolates. Turk J Med Sci. 2016;46(3):892–6.
Hong DJ, Kim JO, Lee H, Yoon EJ, Jeong SH, Yong D, et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2016;86(2):184–9.
Zarakolu P, Ayaz ÇM, Metan G. Karbapeneme dirençli Acinetobacter baumannii enfeksiyonlarının tedavisinde kullanılan çeşitli antibiyotik kombinasyonları ve in vitro sinerji test sonuçları (2002–2016) [Various antibiotic combinations against carbapenem resistant Acinetobacter baumannii infections and in vitro synergy test results (2002–2016)]. Mikrobiyol Bul. 2018;52(2):190–7.
Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN, et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(11):6774–9.
Vourli S, Frantzeskaki F, Meletiadis J, Stournara L, Armaganidis A, Zerva L, et al. Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. Int J Antimicrob Agents. 2015;45(6):670–1.
Ozseven AG, Sesli Çetin E, Ozseven L. Dama Tahtası Sinerji Testi Sonuçlarının Farklı Yöntemlerle Yorumlanması Sonuçlarımızı Etkiliyor mu? [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?]. Mikrobiyol Bul. 2012;46(3):410–20.
Bedenić B, Beader N, Godič-Torkar K, Prahin E, Mihaljević L, Ćačić M, et al. Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp with well defined resistance mechanisms. J Chemother. 2016;28(5):375–82.
Soudeiha MAH, Dahdouh EA, Azar E, Sarkis DK, Daoud Z. In vitro evaluation of the colistin-carbapenem combination in clinical isolates of A baumannii using the checkerboard, Etest, and time-kill curve techniques. Front Cell Infect Microbiol. 2017;7:209.
Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2023. https://doi.org/10.1056/evidoa2200131.
Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am. 2009;23(2):277–93.
Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–303.
Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp: a review of current microbiological and clinical evidence. Int J Antimicrob Agents. 2015;46(3):231–41.
Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24(5):385–93.
Garnacho-Montero J, Dimopoulos G, Poulakou G, Akova M, Cisneros JM, De Waele J, Petrosillo N, Seifert H, Timsit JF, Vila J, Zahar JR, Bassetti M. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41(12):2057–75.
Lu J, Qing Y, Dong N, Liu C, Zeng Y, Sun Q, et al. Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria. Saudi Pharm J. 2022;30(6):849–55.
Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS ONE. 2016;11(6): e0157757.
Tharavichitkul PSC. In vitro synergistic effects of a combination of fosfomycin and colistin against metallo-β-lactamase producing Acinetobacter baumannii. Abstracts of the 31st annual meeting of the Infectious Disease Association of Thailand, Chonburi, Thailand (2005).
Adaleti R, Nakipoğlu Y, Arıcı N, Kansak N, Çalık Ş, Şenbayrak S, et al. Çok İlaca Dirençli Gram-Negatif Basillerde Meropenem/Kolistin ve Meropenem/Fosfomisin Kombinasyonlarının In vitro Etkinliğinin Değerlendirilmesi [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli]. Mikrobiyol Bul. 2023;57(3):365–77.
Martins FS, Zhu P, Heinrichs MT, Sy SKB. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. Br J Clin Pharmacol. 2021;87(3):1012–23.
Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis. 2000;38(1):43–50.
Add Comment